A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
Public ClinicalTrials.gov record NCT06109649. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo
Study identification
- NCT ID
- NCT06109649
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Clinuvel, Inc.
- Industry
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- Afamelanotide and NB-UVB Light Drug
- NB-UVB Light Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 10, 2023
- Primary completion
- Nov 30, 2025
- Completion
- May 31, 2026
- Last update posted
- Jul 7, 2025
2023 – 2026
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CLINUVEL site | Birmingham | Alabama | 00000 | — |
| CLINUVEL site | Fresno | California | 00000 | — |
| CLINUVEL site | Los Angeles | California | 00000 | — |
| CLINUVEL site | Palo Alto | California | 00000 | — |
| CLINUVEL site | San Diego | California | 00000 | — |
| CLINUVEL Site | Washington D.C. | District of Columbia | 00000 | — |
| CLINUVEL site | Miami | Florida | 00000 | — |
| CLINUVEL site | Miramar | Florida | 00000 | — |
| CLINUVEL site | Alpharetta | Georgia | 00000 | — |
| CLINUVEL site | Augusta | Georgia | 00000 | — |
| CLINUVEL site | Chicago | Illinois | 00000 | — |
| CLINUVEL site | Baton Rouge | Louisiana | 00000 | — |
| CLINUVEL site | Detroit | Michigan | 00000 | — |
| CLINUVEL site | Minneapolis | Minnesota | 00000 | — |
| CLINUVEL site | Roseville | Minnesota | 00000 | — |
| CLINUVEL Site | Lee's Summit | Missouri | 00000 | — |
| CLINUVEL site | Rochester | New York | 00000 | — |
| CLINUVEL site | Cleveland | Ohio | 00000 | — |
| CLINUVEL site | Philadelphia | Pennsylvania | 00000 | — |
| CLINUVEL Site | Charleston | South Carolina | 00000 | — |
| CLINUVEL site | Thompson's Station | Tennessee | 00000 | — |
| CLINUVEL Site | Cedar Park | Texas | 00000 | — |
| CLINUVEL site | Dallas | Texas | 00000 | — |
| CLINUVEL site | Tyler | Texas | 00000 | — |
| CLINUVEL site | Charlottesville | Virginia | 00000 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06109649, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06109649 live on ClinicalTrials.gov.